Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Innovative Medicines Initiative: 246 Million Euros To Support Public-private Research Cooperation For A Fast Development Of Better Medicines
Today, 15 new research projects aimed at bringing innovative medicines more quickly to the market have been selected to receive 246 million euros from the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The projects will foster understanding of health issues such as diabetes, pain, severe asthma and psychiatric disorders while increasing drug safety. They will also help improve the training of researchers and clinicians involved in medicines development. The projects were chosen following the first call for proposals launched within the Innovative Medicines Initiative (IMI), a public-private partnership - so called Joint Technology Initiative- between the European Commission and the pharmaceutical industry. With this selection, IMI has reached a key milestone. This initiative marks the first time that pharmaceutical competitors are pooling their res, together with research organisations, patient groups and other stakeholders in large consortia, in order to develop generic, pre-competitive knowledge. The Commission"s contribution of €110 million is backed up with €136 million provided in-kind from the pharmaceutical industry. The successful projects will now enter into the final negotiation phase.
generic viagra online
Cooling Therapy For Cardiac Arrest Survivors Is As Cost-Effective As Accepted Treatments For Other Conditions
Cooling unconscious cardiac arrest survivors can increase survival and has a cost effectiveness comparable to other widely accepted treatments in modern health care, researchers report in Circulation: Cardiovascular Quality and Outcomes.
News of the day
Scientists Test New Drug Combo Against Breast Cancer
The American Cancer Society estimates 192,000 new cases of breast cancer will be diagnosed in the United States this year with more than 40,000 individuals dying from the disease. In New Jersey alone 6,400 new cases are expected with 1,400 deaths. In an effort to combat such statistics, researchers at The Cancer Institute of New Jersey (CINJ) have opened a clinical trial, which will evaluate a new drug combination for patients with breast cancer who are set to undergo surgery to remove the tumor. At focus is the process of stopping angiogenesis (blood vessel growth), which is necessary for cancer tumors to grow and spread. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.
Nutrition

Inviragen Researching Vaccines To Protect Against Pandemic And Seasonal Influenza Viruses

Based on its ongoing avian influenza vaccine research, Inviragen is designing vaccines to protect against multiple influenza strains, including seasonal influenza and the recently emerged H1N1 influenza strain. The H1N1 influenza virus has caused nearly 30,000 cases worldwide in 74 countries leading to 144 deaths. In contrast, while no H5N1 avian influenza strain capable of human-to-human transmission has yet emerged, the high mortality of the virus represents a threat for future epidemics. In addition, conventional seasonal influenza continues to impact public health, causing an estimated 250,000 deaths worldwide every year. Inviragen will leverage its success in designing avian influenza vaccines to identify vaccine candidates that protect against pandemic and seasonal influenza viruses. "Inviragen has successfully developed vaccines that protect animals from lethal H5N1 avian influenza with a single, low dose. Our technology is perfectly suited to engineer a vaccine that will induce protection from avian, swine and human influenza strains," said Dr. Jorge Osorio, Inviragen"s Chief Scientific Officer and Assistant Professor at University of Wisconsin. "Our goal is to develop a vaccine that is easy to manufacture, simple to administer and provides broad protection against multiple influenza viruses." "The recent outbreak of the H1N1 swine-origin influenza highlights the unpredictability of influenza viruses," said Dr. Dan Stinchcomb, Inviragen"s Chief Executive Officer. "Current influenza vaccine manufacturers are scrambling to complete seasonal flu vaccine production and add production of a vaccine for the new H1N1 virus. In the future, Inviragen"s technology could permit manufacture of a single vaccine for both seasonal and pandemic use." The novel H1N1 influenza A virus was first reported in two isolated cases in California and was then found to be identical to the virus causing a severe influenza epidemic in Mexico. In a matter of weeks, the virus spread worldwide, causing thousands of confirmed cases. While the future of the current pandemic is uncertain, it is likely that this H1N1 virus will continue to present a worldwide threat to human health. The avian H5N1 influenza virus emerged in Southeast Asia in 2003 and has caused 433 confirmed human cases leading to 262 deaths (a mortality rate of over 60%). Further virus reassortment or mutation might create an H5N1 virus capable of human-to-human transmission that could cause yet another worldwide flu pandemic. These threats highlight the need for a vaccine that is broadly protective against multiple influenza viruses. Inviragen


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009